Xifaxan Ibsd denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xifaxan ibsd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Xifaxan (rifaximin) for IBS-D as Not Medically Necessary

UnitedHealthcare's medical-necessity denials for Xifaxan (rifaximin) in irritable bowel syndrome with diarrhea (IBS-D) typically reflect a determination that the submitted documentation does not demonstrate the patient meets the clinical criteria outlined in UHC's published coverage policy. Insurers frequently argue that first-line lifestyle, dietary, and conventional pharmacologic interventions have not been adequately trialed, or that the severity documentation is insufficient to justify a branded antibiotic therapy.

This type of denial is routinely overturned on appeal when a complete, well-organized record is submitted — because IBS-D is an FDA-recognized indication for Xifaxan, and the prescriber is best positioned to articulate why the patient's clinical course satisfies coverage requirements.

## Your Appeal Rights

• Internal appeal: Under ERISA §503, employer-sponsored plans must provide a full-and-fair internal review. Submit your appeal in writing within the plan's stated deadline (typically 180 days from the denial notice).
• External review: Under ACA §2719, if the internal appeal is upheld you have the right to an independent external review. The request window is generally within four months of the final internal denial. An independent reviewing organization — not UHC — makes the binding decision.
• Expedited review: If your condition is urgent or a standard timeline would seriously jeopardize your health, you may request expedited internal and external review, often decided within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, symptom history, and any diagnostic workup that establishes IBS-D as the primary diagnosis. 2. Prior-treatment history — a dated list of every prior therapy tried, the duration of each trial, and why each was discontinued (inadequate response, intolerance, or contraindication as documented in the chart). 3. Clinical severity documentation — validated symptom-severity scores, stool-diary records, or clinical notes describing functional impairment and quality-of-life impact. 4. Prescriber medical-necessity letter — a signed, individualized letter (not a form letter) explaining why Xifaxan is appropriate for this patient given the FDA-approved indication, the patient's treatment history, and the relevant guideline recommendations from the applicable professional society. 5. FDA prescribing label excerpt — print the current FDA-approved label for Xifaxan and highlight the IBS-D indication; attach it to demonstrate the on-label nature of the request. 6. UHC policy cross-reference — obtain UHC's current published coverage determination policy for Xifaxan/rifaximin and map each listed requirement to a specific chart fact.

## Criteria-Mapping Structure

Create a table or numbered list that reproduces each requirement from UHC's policy verbatim, then answers it with the exact supporting fact from the patient's chart. For example:

| Policy Requirement | Supporting Documentation | |---|---| | Diagnosis of IBS-D confirmed by a qualified clinician | Office note dated [date], signed by [provider] | | Adequate trial of [prior therapy category per policy] | Pharmacy records + chart note dated [date] | | Symptom severity documented | Validated scale scores in chart, visit [date] |

This structure directly rebuts the insurer's rationale and makes the reviewer's job straightforward. Attach the FDA label and the UHC policy alongside the completed table.